Epidemiology of chronic obstructive pulmonary disease;Épidémiologie de la bronchopneumopathie chronique obstructive

Revue du Praticien

Volumn 54, Issue 13, 2004, Pages 1408-1413

  Roche, Nicolas ^b   Huchon, Gérard ^a  

^a Service de Pneumologie   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DEVELOPED COUNTRY; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; FRANCE; HEREDITY; HUMAN; INHERITANCE; MORTALITY; OCCUPATIONAL EXPOSURE; PREMATURITY; PREVALENCE; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SMOKING; SPIROMETRY;

FRANCE; HUMANS; MORTALITY; OCCUPATIONAL EXPOSURE; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 4544294742     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Société de pneumologie de langue française. Recommandations pour la prise en charge de la bronchopneumopathie chronique obstructive. Rev Mal Respir 2003; 20: 294-329.
2. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-92.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Kurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
4. Vestbo J, Lange P. Can GOLD Stage O provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-32.
5. Mannino DM, Buist AS, Petty TL, Enriqht PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-93.
6. Viegi G, Pedreschi M, Pistelli F et al. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest 2000; 117: 339S-45S.
7. Lange P, Groth S, Nyboe J et al. Chronic obstructive lung disease in Copenhagen: cross-sectional epidemiological aspects. J Intern Med 1989; 226: 25-32.
8. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-9.
9. Pena VS, Miravitlles M, Gabriel R et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-9.
10. Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000; 117: 354S-9S.
11. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press, 1976.
12. Lundback B, Lindberg A, Lindstrom M et al. Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-22.
13. Molinié F, Kauffmann F. Epidémiologie descriptive. In: Huchon 6, Roche N (eds). Bronchopneumopathies chroniques obstructives. Paris: Margaux Orange, 2003: 15-34.
14. Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002; 20: 806-12.
15. Zielinski J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. Chest 2001; 119: 731-6.
16. Lundback B, Lindberg A, Lindstrom M et al. Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-22.
17. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
18. Miravitlles M, Murio C, Guerrero T, Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-55.
19. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19: 623-42.
20. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001; 119: 344-52.
21. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117: 5S-9S.
22. Piperno D, Huchon G, Pribil C, Boucot I, Similowski T. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97: S33-S42.
23. Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-27.
24. Silverman EK, Chapman HA, Drazen JM et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157: 1770-8.
25. Rijcken B, Scheuten JP, Mensinga TT, Weiss ST, De Vries K, Van der LR. Factors associated with bronchial responsiveness to histamine in a population sample of adults. Am Rev Respir Dis 1993; 147: 1447-53.
26. Kanner RE, Connett JE, Altose MD et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994; 150: 956-61.
27. Karakatsani A, Andreadaki S, Katsouyanni K et al. Air pollution in relation to manifestations of chronic pulmonary disease: a nested case-control study in Athens, Greece. Eur J Epidemiol 2003; 18: 45-53.